Long-Term Results of taTME for Rectal Cancer Confirm Efficacy

taTME shows promising long-term outcomes for low rectal cancer patients, crucial for surgical practice.

Three-year overall survival was 93.7%, with disease-free survival at 84.6%.
Late complications in 32 patients, with 21 classified as severe; one required surgical revision.

Surgery can prioritize sphincter preservation without compromising oncologic outcomes.

97% of patients were stoma-free at three years, highlighting successful functional results.

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

More in Intestine and Lower Gastrointestinal Tract

Ann Surg Oncol2 Nov 2026

Patients smoking at diagnosis were less likely to have a favorable response to treatment before rectal cancer surgery; former smokers were not.

JAMA Surg30 Oct 2026

For severe slow-transit constipation, removing less colon gave similar symptom relief at one year, with less early incontinence.

Surg Endosc29 Oct 2026

In low rectal cancer surgery, removing the specimen through the anus was linked to fewer wound complications and less pain in the first two days.